Eribulin + Sacituzumab govitecan + Trastuzumab deruxtecan
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Trial Timeline
Oct 7, 2021 → Jun 1, 2028
NCT ID
NCT04986579About Eribulin + Sacituzumab govitecan + Trastuzumab deruxtecan
Eribulin + Sacituzumab govitecan + Trastuzumab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04986579. Target conditions include Metastatic Breast Cancer, Chemotherapy-induced Alopecia.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04986579 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Breast Cancer